NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy --
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace’s broader AI platform strategy, leveraging the world’s only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed.
ECoG Assistant: Treatment Insights Simplified
ECoG Assistant is the first in a suite of planned NeuroPace AI tools designed to further support clinical decision making through deeper data insights and more efficient ECoG review. Built on years of proprietary, patient-level brain data captured through the RNS® System, ECoG Assistant empowers clinicians to be supported in making faster, more confident treatment decisions.
